Clinical trials
Breast Carcinoma in Situ clinical trials
Below are recruiting breast carcinoma in situ clinical trials, each written for real people, not researchers. We’re tracking 137 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06260033RecruitingPhase 2
Radiation Therapy for Oligoprogressive ER+ Breast Cancer
This trial tests whether a precise radiation treatment (SBRT) can target a few growing spots of estrogen receptor-positive breast cancer that has spread to other parts of the body. It also uses a special PET scan (FES PET/CT) to see how well the cancer responds. The goal is to slow down the cancer and delay the need for stronger treatments.
Duarte, CaliforniaAges 18 years+ - NCT06184750RecruitingPhase 2
Finding the best tamoxifen dose to lower breast cancer risk
This trial tests different doses of tamoxifen to find the best one for lowering breast cancer risk in premenopausal women. It aims to see if a lower dose works as well as the standard dose with fewer side effects.
Tucson, ArizonaAges 18–55 - NCT06195306RecruitingPhase 2
Low dose tamoxifen and omega-3 for breast cancer prevention
This study tests whether low-dose tamoxifen (a breast cancer prevention drug) or omega-3 supplements can lower breast cancer risk in postmenopausal women who are overweight and have a higher chance of getting the disease. The study lasts about 6 months and involves blood draws and a breast fluid test to see how the treatment affects breast cells.
Kansas City, KansasAges 45–74 - NCT06202118Recruiting
Alpha radiation therapy for breast cancer in older or frail patients
This trial tests a new type of radiation therapy (DaRT) that uses tiny, implantable seeds to deliver targeted alpha radiation to breast tumors. It is designed for older patients (65+) or those who are too frail for surgery, offering a less invasive option for controlling the cancer.
JerusalemAges 65–120 - NCT05677802Recruiting
Stress-reduction program for newly diagnosed triple-negative breast cancer
This study tests whether a structured stress-reduction program can help people with newly diagnosed triple-negative breast cancer (stages I–III). The goal is to see if the program is practical and beneficial for patients during treatment.
Cleveland, OhioAges 18 years+ - NCT06179303RecruitingPhase 2
Imaging to predict response to abemaciclib for advanced breast cancer
This trial tests if a special PET scan can predict how well the drug abemaciclib works for people with advanced hormone receptor-positive, HER2-negative breast cancer. If you qualify, you would receive abemaciclib and have imaging scans to see if your cancer responds.
St Louis, MissouriAges 18 years+ - NCT06176261RecruitingPhase 2
Datopotamab deruxtecan for breast cancer with brain spread
This trial tests a new drug called datopotamab deruxtecan for people with HER2-negative breast cancer that has spread to the brain. It looks at how well the drug works against brain metastases.
Miami, FloridaAges 18 years+ - NCT06115486Recruiting
Exercise to improve muscle after breast cancer treatment
This trial tests whether a structured exercise program (called EXERT-BCH) can help improve muscle mass in women who have finished breast cancer treatment. It involves group resistance training sessions and is designed to support recovery and strength.
Pittsburgh, PennsylvaniaAges 20–89 - NCT05941520RecruitingPhase 2
Acolbifene vs low-dose tamoxifen to prevent breast cancer
This Phase 2 trial compares acolbifene and low-dose tamoxifen to see which better lowers breast cancer risk in premenopausal women at high risk. You would be followed with health visits, blood tests, and a breast tissue sampling procedure.
Duarte, CaliforniaAges 35 years+ - NCT05464810RecruitingEarly Phase 1
Letrozole with or without a cholesterol drug for early breast cancer
This early-phase study tests whether adding simvastatin to letrozole can improve outcomes in people with stage I–III breast cancer that grows with hormone signals (hormone receptor positive) and does not have HER2. It looks mainly at whether the approach is safe and useful for this specific breast cancer type.
Atlanta, GeorgiaAges 18 years+ - NCT05422794RecruitingPhase 1
Adding a new drug plus pembrolizumab to standard chemo for TNBC
This trial studies whether adding a new anti-cancer drug (ZEN-3694) and the immunotherapy drug pembrolizumab to standard chemotherapy (nab-paclitaxel) can work better for advanced triple-negative breast cancer. It’s testing safety first (Phase 1) and, for some patients, how well the treatment controls the cancer.
Boston, MassachusettsAges 18 years+ - NCT05372640RecruitingPhase 1
Drug combo trial for rare cancers with shared NUT features
This Phase 1 trial tests the safety and early signs of effectiveness of combining two anti-cancer drugs (ZEN003694 and abemaciclib) in teens and adults with metastatic or unresectable NUT carcinoma, breast cancer, and other solid tumors. It may help by finding a safer dose and whether the drug combination can shrink or control tumors that do not respond to standard treatments.
Los Angeles, CaliforniaAges 12 years+ - NCT05092373RecruitingPhase 1
Tumor treating device plus targeted or immune drugs for advanced cancers
This Phase 1 study tests whether a tumor treating fields device works better when added to standard cancer drugs. It may help people with advanced solid tumors in the chest or belly, especially when standard treatment didn’t work or can’t be tolerated.
Houston, TexasAges 18 years+ - NCT05098210RecruitingPhase 1
Personalized vaccine made from your tumor’s new immune targets
This Phase 1 study tests a customized vaccine made from “neo-antigens,” which are new targets found in your tumor. It aims to help your immune system fight certain advanced cancers that have not responded well to prior treatment.
Seattle, WashingtonAges 18 years+ - NCT04959474Recruiting
Pre-surgery radiation study with or without calorie restriction
This trial looks at whether a planned calorie-reduction diet before surgery can change how early breast cancer responds to a short course of radiation. It may help people understand if diet could improve outcomes alongside standard pre-surgery treatment.
Philadelphia, PennsylvaniaAges 40 years+ - NCT04790305RecruitingPhase 4
Huaier granules with standard therapy for early triple-negative breast cancer
This trial looks at whether adding Huaier granules to usual after-surgery treatment can improve outcomes for people with high-risk early-stage triple-negative breast cancer. It focuses on whether the added supplement is safe and helpful after standard care.
Hefei, AnhuiAges 18–70 - NCT04603209Recruiting
Check-in registry for radiation during breast-conserving surgery
This registry study tracks people with early-stage, single-area breast cancer to understand outcomes when radiation is given during breast-conserving surgery. It may help doctors improve treatment planning for patients like you.
Santa Monica, CaliforniaAges 18 years+ - NCT04521764RecruitingPhase 1
Vaccine for Metastatic Breast Cancer
This trial tests a vaccine (MV-s-NAP) that is injected directly into a tumor to stimulate your immune system against breast cancer. It is for people with metastatic breast cancer that has spread despite prior treatments.
Rochester, MinnesotaAges 18 years+ - NCT04305834RecruitingPhase 2
Abemaciclib plus hormone pills for metastatic breast cancer in older adults
This Phase 2 study tests whether abemaciclib combined with standard hormone (endocrine) therapy can better control metastatic breast cancer in people age 70 and older. It may help if your cancer has already grown despite prior hormone therapy and/or other cancer medicines.
Duarte, CaliforniaAges 70 years+ - NCT04084730RecruitingPhase 2
3-day radiation after breast-conserving surgery for certain breast cancers
This trial tests whether a shorter, 3-day course of partial breast radiation after surgery works as well as standard radiation for women with early-stage breast cancer. It may help reduce time in treatment while aiming to keep cancer from coming back in the treated breast area.
Norwalk, ConnecticutAges 45 years+ - NCT04074720Recruiting
Collecting breast cancer tissue and blood samples
This study collects tissue and/or blood samples from people with breast cancer to help future research. It may be useful if you’re already having surgery or another procedure as part of your treatment plan.
Philadelphia, PennsylvaniaAges 18 years+ - NCT04144023RecruitingPhase 1
Vaccine before surgery for HER2-positive breast duct cancer in place
This Phase 1 study tests a vaccine (H2NVAC) given before surgery to help the body fight HER2-expressing ductal carcinoma in situ (DCIS) that has not been removed yet. Because it’s early-stage, the main goal is to check safety and learn how the treatment may work.
Jacksonville, FloridaAges 18 years+ - NCT04090567RecruitingPhase 2
Olaparib with two partners for advanced BRCA breast cancer
This trial tests whether the drug olaparib works better when combined with cediranib or AZD6738 in people with advanced or metastatic BRCA (inherited) breast cancer. It may help shrink tumors or slow cancer growth after prior treatment with a PARP inhibitor.
Houston, TexasAges 18 years+ - NCT03909282Recruiting
Surgery now versus radiation then delayed surgery for DCIS
This trial compares two approaches for ductal carcinoma in situ (DCIS): having surgery first versus getting radiation first and then having surgery later. It aims to see which plan controls DCIS better while affecting treatment timing and outcomes.
Stanford, CaliforniaAges 18 years+
Hear when a new Breast Carcinoma in Situ trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for breast carcinoma in situ?
- Yes. Clin2 currently lists 137 recruiting breast carcinoma in situ studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a breast carcinoma in situ trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a breast carcinoma in situ trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.